• 26 Sep, 2026
• SendClinic
• comments off

What Is Paxlovid & When Is It Prescribed? | SendClinic

A COVID-19 Treatment You May Have Heard About

You test positive for COVID-19 and start wondering what you can do beyond rest and fluids. A friend mentions Paxlovid, your neighbor said their doctor prescribed it, and now you want to know if it might help you too. It is a fair question. Paxlovid became one of the most talked-about COVID-19 treatments since it became available, and understanding what it is and who it is meant for can help you have a better conversation with your provider.

This article breaks down what Paxlovid is, how it works, who may be a good candidate, and what to keep in mind if you think it might be right for you. As always, only a licensed medical provider can decide whether this medication is appropriate for your specific situation.

What Is Paxlovid?

Paxlovid is an antiviral medication made by Pfizer. It is taken by mouth, which makes it different from some earlier COVID-19 treatments that required an IV. The full name of the drug combination is nirmatrelvir and ritonavir. These two medicines work together as a team inside your body.

Nirmatrelvir is the main antiviral component. It works by blocking a specific enzyme that the SARS-CoV-2 virus needs to make copies of itself. When the virus cannot replicate as easily, your body has a better chance of fighting off the infection. Ritonavir is added not because it fights the virus directly, but because it slows down the breakdown of nirmatrelvir in your body, allowing it to stay active longer and at higher levels.

Paxlovid is taken as a set of pills twice a day for five days. Because of how it interacts with the body, timing matters. It is generally meant to be started within five days of symptom onset to be most effective.

How Did Paxlovid Get Approved?

The U.S. Food and Drug Administration (FDA) first authorized Paxlovid under an Emergency Use Authorization (EUA) in December 2021. After further review of safety and effectiveness data, the FDA granted Paxlovid full approval in May 2023 for adults who are at high risk of severe COVID-19. This means it went through the standard approval process, not just emergency authorization.

The approval was based on clinical trial data showing that Paxlovid reduced the risk of hospitalization and death in high-risk adults with mild to moderate COVID-19 when taken early. The trial that supported authorization showed meaningful results in people who had not been vaccinated and who had risk factors for serious illness.

It is important to understand that full FDA approval applies to a specific population — adults at high risk of progressing to severe disease. This is why not everyone with COVID-19 will be offered this medication.

Who May Be a Candidate for Paxlovid?

Paxlovid is generally considered for adults who have mild to moderate COVID-19 symptoms but who are at high risk of becoming seriously ill. High-risk factors can include older age, obesity, diabetes, heart disease, chronic kidney or lung disease, being immunocompromised, and other conditions that make the body less able to fight off infection. Your provider will look at your overall health picture when deciding if it is appropriate.

The medication is not intended for people who are already hospitalized with severe COVID-19, or for people who are at low risk and likely to recover on their own. It is also not currently approved for use in children, though research in younger populations continues.

Because Paxlovid interacts with a large number of other medications, your provider will need to review your full medication list carefully before prescribing it. Some drug interactions can be serious, so this step is very important. Never take Paxlovid obtained from any source other than a licensed pharmacy with a valid prescription.

What Is “Paxlovid Rebound”?

You may have heard the term “Paxlovid rebound.” This refers to a situation where some people experience a return of COVID-19 symptoms or test positive again shortly after finishing the five-day course of treatment. This phenomenon was reported even before Paxlovid existed, suggesting it may be related to the natural course of COVID-19 in some people rather than the medication itself.

The CDC has acknowledged that rebound symptoms have been reported and appear to be generally mild. Researchers are still studying why this happens and how common it truly is. If you finish a course of Paxlovid and feel better but then feel worse again, it is a good idea to contact your provider.

Rebound does not necessarily mean the treatment failed. It simply means your situation needs continued monitoring, and your provider can guide you on next steps based on your symptoms.

How Do You Get a Paxlovid Prescription?

You need a prescription from a licensed healthcare provider to get Paxlovid. That means you will need to speak with a doctor, nurse practitioner, or physician assistant who can review your symptoms, medical history, current medications, and risk factors. This kind of visit can now happen quickly and conveniently through telehealth.

If you test positive for COVID-19 and are wondering whether Paxlovid might be right for you, acting quickly matters because the window for starting treatment is narrow. SendClinic offers fast video and phone visits with licensed providers, so you do not have to wait days for an appointment or sit in a waiting room when you are already feeling sick.

Once a prescription is issued, Paxlovid can be filled at most major pharmacies. Cost and coverage can vary, so it is worth checking with your pharmacy or insurance provider about what applies to your situation.

Talk to a Provider About Your Options

COVID-19 affects everyone differently. Some people have a mild week of fatigue and congestion. Others, especially those with certain health conditions, are at greater risk of serious illness. Knowing that an antiviral treatment option like Paxlovid exists — and understanding who it is meant for — is a helpful step in taking charge of your health.

If you test positive and are unsure what to do next, do not guess. Reach out to a licensed medical provider as soon as possible. The sooner you get evaluated, the more options may be available to you. SendClinic makes it easy to connect with a provider from home, without insurance or a long wait.

References

• U.S. Food and Drug Administration. “FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults.” FDA.gov. 2023.
• Hammond, Jennifer, et al. “Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.” New England Journal of Medicine. 2022.
• Centers for Disease Control and Prevention. “COVID-19 Rebound After Paxlovid Treatment.” CDC.gov. 2022.
• National Institutes of Health. “COVID-19 Treatment Guidelines: Antiviral Therapy.” NIH.gov. 2023.
• Dryden-Peterson, Scott, et al. “Nirmatrelvir Plus Ritonavir and Symptoms at 30 Days in Outpatients with Mild-to-Moderate COVID-19.” JAMA Internal Medicine. 2023.